A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology. Dermavant leverages the Roivant platform to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

Dermavant Voices: Patient‑Focused Innovation

“THE ABILITY TO TRANSFORM LIVES”

Todd Zavodnick, Chief Executive Officer

“A PASSION FOR HELPING PEOPLE”

 Philip M Brown, MD, JD, Chief Medical Officer

“FUNDAMENTALLY CHANGING THE LIVES OF PATIENTS”

David Rubenstein, MD, PhD, Chief Scientific Officer

Latest News

June 16, 2020

Dermavant Announces Publication in JAAD of Seconda ...

Read More

June 9, 2020

Dermavant Completes Patient Enrollment for Long-Te ...

Read More

May 26, 2020

Dermavant Announces Publication in JAAD of Seconda ...

Read More